can transferrin abs safely open the bbb, page-4

Hi Wayne,

Thanks for your post.

Agree, there sure are a number of interesting points.

As we've previously discussed, the Genetech video that you posted a while back "How to Get Into the Brain" describes the transferrin receptor technology, which is what I believe that Phylogica are looking to improve upon with their 2nd generation libraries.

I had another read of the 2011 article;

http://www.alzforum.org/new/detail.asp?id=2802#

Not surprising...

What most excited scientists interviewed for this article is the potential of this low-affinity transcytosis technique to deliver antibodies into the brain. Several researchers suggested that making a bispecific antibody with anti-Aß would be a logical step for AD research. Watts pointed out that other transcytosis pathways might work better than the transferrin receptor. “We believe this is a broad principle. Reducing affinity for a receptor-mediated transcytosis target will enhance antibody uptake,” Watts said. “We are very keen on using this technology to go after CNS diseases.”—Madolyn Bowman Rogers

and...

The principles may be broadly applicable to other strategies to penetrate the blood-brain barrier (BBB), Watts suggested. Several companies are working on similar drug delivery systems, which may eventually help clinicians administer medications for the treatment of Alzheimer’s disease or other neurodegenerative disorders. “It’s essential for the field to find a way to deliver large molecules to the brain,” Watts said.

http://www.alzforum.org/new/detail.asp?id=3480#

You wrote:

What does all this mean for BEN? We do know that, as late as the Perth Showcase Lunch, Paul Watt intently stated that "[Phylogica have] achieved the milestones on all of our Pharma relationships." By extension, it means that phylomer peptides which cross the BBB have been delivered to Genentech in accordance with the milestone agreement. We also understand that there is data on the BEN phylomer peptides which is 'exciting'.

From CFO, Nick Woolf:

When screening for CPPs, some peptides penetrate the cell wall but are trapped in endosomes inside the cell. These (false positives) do not then deliver their cargo
inside the cell. The real CPPs are those that can escape from endosomes and deliver their payload. We have developed a technology that allows us only to detect CPPs that escape the endosome and deliver their cargo. These are the aces.

It shouldn't be too long now before we find out about BEN_5000 Phylomer.

Definitely and interesting time to be invested!

Regards,
Tony